EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
Post-LOEemtricitabine, rilpivirine, tenofovir disoproxil fumarate
ANDAORALTABLET
Approved
May 2025
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE (emtricitabine, rilpivirine, tenofovir disoproxil fumarate) by Viatris (2) is nucleoside reverse transcriptase inhibitors [moa]. First approved in 2025.
Drug data last refreshed 19h ago
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Viatris (2)
China - Shanghai
Worked on EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.